Home >
Keywords
This list of keywords links to the Pubmed website. Simply click on a keyword to display its associated articles.
Overview of psoriasis | Physiopathology | Clinical features | Age of life | Psoriasis in pregnancy | Psoriatic arthritis | Triggers factors | Associated conditions | Clinical severity instruments | Patient informations | Therapy | Topical Treatment | Systemic treatments | Biologicals | Diet and psoriasis
Clinical features
- Complications
- Diagnosis
- Diagnosis, Differential
- Erythrodermic psoriasis
- Eye
- Facial psoriasis
- Guttate psoriasis
- Hallopeau
- Inverse psoriasis
- Mortality
- Nail psoriasis
- Oral Manifestations
- Palmoplantar
- Palmoplantar pustular psoriasis
- Pruritus
- Psoriasis congenital
- Psoriasis vulgaris
- Pustular psoriasis
- Scalp psoriasis
- Sebopsoriasis
SPIN Presentation
Recent news
- 2019/10/29 Focus on...
- 2019/08/12 Focus on...
Latin American Clinical Practice Guidelines on the Systemic Treatment of Psoriasis
- 2019/06/03 Focus on...
- 2019/05/21 Focus on...
- 2019/04/18 Focus on...
News from the web office
- 2016/10/29
- 2016/05/26
- 2016/02/20
Events
- 2019/04/18 Focus on...
- 2018/02/21
News from medical groups
- 2018/04/18
- 2017/06/21
News from patients associations
- 2017/02/08
- 2016/05/26
Recent publications on Psoriasis and Atopic Dermatitis
on Psoriasis
Off-label studies on apremilast in dermatology: a review.
Maloney NJ et al.
Off-label studies on apremilast in dermatology: a review.
J Dermatolog Treat.
2020 Mar , 31, (2):131-140.
Apremilast is a phosphodiesterase-4 inhibitor FDA approved for psoriatic arthritis and moderate to severe plaque psoriasis. In recent years, multiple studies have suggested other potential uses for apremilast in dermatology. A summary of these various studies will be a valuable aid to dermatologists considering apremilast for an alternative indication. The PubMed/MEDLINE and ClinicalTrials.gov databases were queried with the term 'apremilast,' with results manually screened to identify (...)
see on pubmed
Our ambition in a changing landscape of psoriasis treatments.
van de Kerkhof PCM et al.
Our ambition in a changing landscape of psoriasis treatments.
J Dermatolog Treat.
2020 Mar , 31, (2):105-107.
CARD14/CARMA2sh and TANK differentially regulate poly(I:C)-induced inflammatory reaction in keratinocytes.
J. Cell. Physiol..
2020 Mar , 235, (3):1895-1902.
CARD14/CARMA2sh (CARMA2sh) is a scaffold protein whose mutations are associated with the onset of human genetic psoriasis and other inflammatory skin disorders. Here we show that the immunomodulatory adapter protein TRAF family member-associated NF-κB activator (TANK) forms a complex with CARMA2sh and MALT1 in a human keratinocytic cell line. We also show that CARMA2 and TANK are individually required to activate the nuclear factor κB (NF-κB) response following exposure to (...)
see on pubmed
on Atopic Dermatitis
Off-label studies on apremilast in dermatology: a review.
Maloney NJ et al.
Off-label studies on apremilast in dermatology: a review.
J Dermatolog Treat.
2020 Mar , 31, (2):131-140.
Apremilast is a phosphodiesterase-4 inhibitor FDA approved for psoriatic arthritis and moderate to severe plaque psoriasis. In recent years, multiple studies have suggested other potential uses for apremilast in dermatology. A summary of these various studies will be a valuable aid to dermatologists considering apremilast for an alternative indication. The PubMed/MEDLINE and ClinicalTrials.gov databases were queried with the term 'apremilast,' with results manually screened to identify (...)
see on pubmed
Atopic dermatitis induces anxiety- and depressive-like behaviors with concomitant neuronal adaptations in brain reward circuits in mice.
Prog. Neuropsychopharmacol. Biol. Psychiatry.
2020 Mar 02, 98:109818.
Clinically, it has been reported that atopic dermatitis (AD) has been linked with negative emotional problems such as depression and anxiety, thereby reducing the quality of life, but little is known about the molecular mechanism that underlies AD-associated emotional impairments. We sought to determine whether AD could induce anxiety- and depressive-like symptoms in mice and to identify pertinent signaling changes in brain reward circuitry. AD-like lesions were induced by the repeated (...)
see on pubmed
Efficacy and safety of indigo naturalis ointment in Treating Atopic Dermatitis: A randomized clinical trial.
J Ethnopharmacol.
2020 Mar 25, 250:112477.
Indigo naturalis, a herbal medicine with a history of use dating back to ancient times, may be a good alternative topical treatment for atopic dermatitis (AD).
see on pubmed
